3rd May 2012 09:30
Sinclair IS Pharma plc
Director Shareholding
Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair IS" or the "Company"), the international specialty pharma company, announces that 139,650 new ordinary 1p shares in the Company have been issued to satisfy Performance Share Awards that have vested under the 2003 Executive Share Incentive Plan to certain Director's and employees. Application for the new shares has been made to AIM and these are expected to be admitted to trading on 9 May 2012.
Shares have been issued to the following Director and PDMR's:
Name | Price paid per share |
Shares allotted | Total shareholding post award
|
% of issued share capital | |
Christophe Foucher, Chief Operating Officer | 1p | 45,000 | 156,200 | 0.04% | |
Alan Olby, Chief Financial Officer | 1p | 24,750 | 123,090 | 0.03% | |
Stephen Redman, Company Secretary | 1p | 28,500 | 68,517 | 0.02% | |
Ends
For further information please contact:
Sinclair IS Pharma plc | Tel: +44 (0) 20 7467 6920 |
Chris Spooner Alan Olby Robert Taylor | |
Jefferies Hoare Govett (NOMAD and Broker) | Tel: +44 (0) 20 7029 8000 |
Nick Adams Thomas Rider | |
FTI Consulting | Tel: +44 (0) 20 7831 3113 |
Ben Atwell Stephanie Cuthbert |
Additional information as required under the AIM Rules
Following this issue of new shares, which rank pari passu with the Company's existing ordinary shares, the Company will have 402,583,065 ordinary 1p shares in issue, each share carrying the right to one vote. The Company does not hold any ordinary shares in Treasury.
The above figure of 402,583,065 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Services Authority's Disclosure and Transparency Rules.
Notes to Editors:
About Sinclair IS Pharma plc - www.sinclairispharma.com
Sinclair IS Pharma is an international specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through advanced surface technology and innovative delivery systems. The Company has a growing sales and marketing operation with a direct sales presence in the top five European markets and an extensive marketing partner network across selected developed and emerging markets.
Related Shares:
Sinclair Pharma